 |
市場調查報告書
商品編碼
1544825
眼科眼藥水市場、機會、成長動力、產業趨勢分析與預測，2024-2032Ophthalmic Eye Dropper Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032 |
||||||
在產品推出和技術進步激增的推動下，2024 年至 2032 年眼科滴管市場規模預計將以 6.7% 的複合年成長率成長。
該公司正在推出新的滴管型號，強調精度和方便用戶使用性方面的尖端創新。這些進步不僅提高了劑量準確性，也提升了整體使用者體驗。此外，人體工學設計、防篡改包裝和複雜的跌落控制機制等功能正在被整合，使眼睛護理更加有效。例如，2023年6月，博士倫公司在美國推出了含有輔酶Q10的PreserVision AREDS 2 Formula軟膠囊，拓寬了眼科解決方案的範圍，並強調了該行業對推進眼部健康產品的承諾。
整個市場分為眼藥水類型、模式、適應症、最終用途和地區。
根據眼藥水類型，預計單劑量眼藥水領域的眼科眼藥水市場價值將從2024 年到2032 年以顯著速度成長。越來越多的青睞。透過提供一次性應用，這些滴管可最大限度地降低污染風險並提高劑量準確性，確保無菌和方便用戶使用的體驗。
預計到2032 年，青光眼適應症領域的眼科眼藥水產業將以顯著的複合年成長率擴張。 。透過有效降低眼內壓，這些滴管在青光眼治療中發揮關鍵作用，強調了它們在維持最佳眼睛健康方面的重要性。
在人口老化不斷擴大的推動下，歐洲眼科眼藥水市場預計將在 2024 年至 2032 年間實現強勁成長。隨著老年人口的增加，對有效的眼部護理解決方案的需求不斷增加。白內障、青光眼和乾眼症等疾病變得越來越普遍，眼藥水提供了解決這些挑戰的便捷方法。隨著歐洲應對老齡化人口不斷變化的需求，眼部護理解決方案（包括眼藥水）的持續創新將至關重要。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 眼部疾病盛行率增加
- 眼科藥物傳輸系統的技術進步
- 老年人口增加與疾病相伴
- 提高認知和診斷
- 產業陷阱與挑戰
- 不合規和依從性差
- 相關副作用和耐受性問題
- 成長動力
- 成長潛力分析
- 2018-2032 年無防腐劑多劑量眼藥水體積分析
- 監管環境
- 技術景觀
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按滴管類型，2018 - 2032 年
- 主要趨勢
- 單劑量眼藥水
- 保存多劑量滴眼器
- 不含防腐劑的多劑量眼藥水
第 6 章：市場估計與預測：按模式，2018 - 2032
- 主要趨勢
- 處方藥
- 非處方 (OTC) 藥物
第 7 章：市場估計與預測：按指標分類，2018 年 - 2032 年
- 主要趨勢
- 青光眼
- 過敏
- 結膜炎
- 乾眼症
- 其他適應症
第 8 章：市場估計與預測：依最終用途，2018 年 - 2032 年
- 主要趨勢
- 醫院
- 眼科診所
- 家庭護理設置
- 其他最終用戶
第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 10 章：公司簡介
- AbbVie Inc.
- Alcon Inc.
- AdvaCare Pharma
- Bausch Health Companies Inc.
- Dompe Farmaceutici S.p.A
- Novartis AG
- Pfizer Inc.
- PanOptica, Inc.
- Prestige Consumer Healthcare Inc.
- Sun Pharmaceutical Industries Ltd.
Ophthalmic Eye Dropper Market size is projected to grow at a 6.7% CAGR from 2024 to 2032, fueled by a surge in product launches and technological advancements.
Companies are unveiling new eye dropper models, emphasizing cutting-edge innovations in precision and user-friendliness. These advancements not only enhance dosing accuracy but also elevate the overall user experience. Furthermore, features like ergonomic designs, tamper-evident packaging, and sophisticated drop control mechanisms are being integrated, making eye care more effective. For instance, in June 2023, Bausch + Lomb Corporation launched its PreserVision AREDS 2 Formula soft gels with CoQ10 in the U.S., broadening the spectrum of ophthalmic solutions and underscoring the industry's commitment to advancing eye health products.
The overall market is segregated into eye dropper type, mode, indication, end-use, and region.
Based on eye dropper type, the ophthalmic eye dropper market value from the unidose eye dropper segment is forecasted to rise at a notable rate from 2024 to 2032. This is attributed to the growing preference for unidose eye droppers for their convenience and precision. By offering single-use applications, these droppers minimize contamination risks and enhance dosing accuracy, ensuring a sterile and user-friendly experience.
Ophthalmic eye dropper industry from the glaucoma indication segment is anticipated to expand at a significant CAGR through 2032. This is largely due to the critical role eye droppers play in managing glaucoma, delivering precise medication doses directly to the eye. By effectively reducing intraocular pressure, these droppers are pivotal in glaucoma management, underscoring their importance in maintaining optimal eye health.
Europe ophthalmic eye dropper market is set for robust growth between 2024 and 2032, driven by the expanding aging population. With the elderly demographic on the rise, there is an escalating demand for effective eye care solutions. Conditions like cataracts, glaucoma, and dry eye syndrome are becoming more prevalent, and eye droppers offer a convenient means to address these challenges. As Europe navigates the evolving needs of its aging population, continued innovations in eye care solutions, including eye droppers, will be paramount.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of eye disorders
- 3.2.1.2 Technological advancements in ophthalmic drug delivery systems
- 3.2.1.3 Increasing geriatric population coupled with disease
- 3.2.1.4 Increasing awareness and diagnosis
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Non-compliance and poor adherence
- 3.2.2.2 Associated side effects and tolerance issues
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Volume analysis of preservative-free multi-dose eye dropper, 2018-2032
- 3.5 Regulatory landscape
- 3.6 Technological landscape
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Competitive positioning matrix
- 4.4 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Eye Dropper Type, 2018 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Unidose eye dropper
- 5.3 Preserved multi-dose eye dropper
- 5.4 Preservative-free multi-dose eye dropper
Chapter 6 Market Estimates and Forecast, By Mode, 2018 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Prescription drugs
- 6.3 Over the counter (OTC) drugs
Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Glaucoma
- 7.3 Allergies
- 7.4 Conjunctivitis
- 7.5 Dry eye
- 7.6 Other indications
Chapter 8 Market Estimates and Forecast, By End-use, 2018 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospitals
- 8.3 Ophthalmic clinics
- 8.4 Homecare settings
- 8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 AbbVie Inc.
- 10.2 Alcon Inc.
- 10.3 AdvaCare Pharma
- 10.4 Bausch Health Companies Inc.
- 10.5 Dompe Farmaceutici S.p.A
- 10.6 Novartis AG
- 10.7 Pfizer Inc.
- 10.8 PanOptica, Inc.
- 10.9 Prestige Consumer Healthcare Inc.
- 10.10 Sun Pharmaceutical Industries Ltd.
